Showing results (91-100 of 184) with videos related to
Sort By:
Pageof 19
Oncology Letters|September 21, 2017
Bortezomib, carfilzomib and ixazomib do not mediate relevant transporter-based drug-drug interactionsJannick Clemens, Lukas Welti, Julia Schäfer, et al.Archives of Toxicology|October 13, 2023
Rifabutin but not rifampicin can partly out-balance P-glycoprotein induction by concurrent P-glycoprotein inhibition through high affinity binding to the inhibitory siteLottida Phondeth, Rajamanikkam Kamaraj, Julie Nilles, et al.Analytical Biochemistry|March 1, 2020
Reporter cell assay-based functional quantification of TNF-α-antagonists in serum - a proof-of-principle study for adalimumabLukas Schuster, Max Sauter, Philipp Uhl, et al.Pharmaceutics|August 26, 2022
Evaluation of PepT1 (SLC15A1) Substrate Characteristics of Therapeutic Cyclic PeptidesGzona Bajraktari-Sylejmani, Teresa von Linde, Jürgen Burhenne, et al.The Journal of Antimicrobial Chemotherapy|March 12, 2011
Potential of novel antiretrovirals to modulate expression and function of drug transporters in vitroNadine Cécile Luise Zembruski, Gabriele Büchel, Lisa Jödicke, et al.Journal of Pharmacological Sciences|February 24, 2009
Induction of multiple drug transporters by efavirenzJohanna Weiss, Melanie Herzog, Sonja König, et al.The Journal of Antimicrobial Chemotherapy|June 15, 2013
Steady-state pharmacokinetics and metabolism of voriconazole in patientsMarcus J P Geist, Gerlinde Egerer, Jürgen Burhenne, et al.Journal of Chromatography. A|May 1, 2014
Stability of the proteasome inhibitor bortezomib in cell based assays determined by ultra-high performance liquid chromatography coupled to tandem mass spectrometryJannick Clemens, Magdalena Longo, Anja Seckinger, et al.Archives of Toxicology|January 4, 2024
In vitro evaluation of the reductive carbonyl idarubicin metabolism to evaluate inhibitors of the formation of cardiotoxic idarubicinol via carbonyl and aldo-keto reductasesGzona Bajraktari-Sylejmani, Julia Sophie Oster, Jürgen Burhenne, et al.Journal of Clinical Pharmacology|December 15, 2010
Daily honey consumption does not change CYP3A activity in humansLeonie Fetzner, Jürgen Burhenne, Johanna Weiss, et al.Pageof 19